Urinary Tract News
-
Infection Prevention through Clean Water: How Healthcare Facilities Can Mitigate Healthcare-Associated Infections from Water
Healthcare-associated infections or HAIs are infections people get while they are receiving health care for another condition. These infections can happen in all types of healthcare settings and are a significant cause of patient illness and death. According to the Centers for Disease Control and Prevention (CDC), 1 in 31 patients experience a healthcare-associated infection on any given day, ...
-
Infection Control Resources to Safeguard Patients and Building Occupants from Acinetobacter and Other Pathogens
The Centers for Disease Control and Prevention describe Acinetobacter as a group of bacteria commonly found in the environment in places like soil and water. While there are many types, the most frequent cause of infections in humans is known as Acinetobacter baumannii. Those most at risk of infection according to the CDC include patients in hospitals, especially those who: · are ...
-
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study and further demonstrated the rapid improvements in depressive symptoms observed in the clinical ...
-
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- Alnylam ...
-
FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
LYTGOBI (pronounced “light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI covalently binds to FGFR2 and inhibits the signaling pathway. The other approved FGFR inhibitors are reversible ATP-competitive inhibitors. LYTGOBI previously received breakthrough, orphan drug ...
-
Viveve to Participate in Ladenburg Thalmann Healthcare Conference
ENGLEWOOD, CO / ACCESSWIRE / September 22, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, September 29, 2022, in New York City. Mr. Durbin will deliver the Viveve ...
-
Viveve to Participate in Alliance Global Partners Virtual MedTech Conference
ENGLEWOOD, CO / ACCESSWIRE / September 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Alliance Global Partners Virtual MedTech Conference, September 21, 2022. Mr. Durbin will provide an update on Viveve's ...
-
NYMOX Provides Current Update
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business developments. The Company has corresponded with and has met with the FDA during the past few months. The agency has provided very helpful feedback to the Company. FDA has specified what additional information is required in resubmission of the NDA; and the Company is in the process of preparing the ...
-
Interim results of the Expander-1 Clinical Study
Medeon Biodesign, Inc. (TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign Prostatic Hyperplasia (BPH) treatment solution. XFLO offers a reversible and office-based treatment option for patients who are ...
-
Caldera Medical Announces FDA Clearance for New Desara TVez for Stress Urinary Incontinence
Caldera Medical, a medical device company that develops best-in-class surgical products for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse, and Polyps announced the launch of Desara® TVez, an expansion to their Desara® Family of products. “Staying true to our commitment of being surgeon and patient focused, Caldera Medical collaborated with dozens of leading ...
-
Locus Biosciences Announces $35 Million Financing
Proceeds will support product development and expansion of in-house cGMP manufacturing capabilities Company anticipates initiating Phase 2 trial of CRISPR-Cas3-enhanced bacteriophage precision medicine for UTIs mid-2022 Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse ...
-
Research Suggests COVID-19 Affects Erectile Function
"One of the repercussions of COVID-19 is its impact on men's sexual health. COVID-19 infection is expected to be associated with an increased likelihood of erectile dysfunction (ED). Considering the high transmissibility of COVID-19, ED could be a concerning consequence for a large segment of the population" https://www.ncbi.nim.nih.gov/pmc/articles/PMC8450276/. Coincidentally, DirexGroup ...
By DirexGroup
-
Etienne Jornod, Om Pharma‘S Executive Chairman Receives Swiss Biotech Success Stories Award 2022
OM Pharma is pleased to announce that Etienne Jornod, its Executive Chairman and co-owner, has been recognised as winner of the Swiss Biotech Success Stories Awards 2022. The awards, bestowed annually by the Swiss Biotech Association, celebrates those who have made important and sustainable contributions to the biotech industry in Switzerland. The Swiss entrepreneur was particularly ...
-
The transformation of precision medicine in infectious disease
Before Alexander Fleming discovered penicillin, another more selective antibacterial agent rose to popularity in the early 1900s: bacteriophage. In 1917, microbiologist Felix d’Herelle was tasked with identifying the cause of a dysentery outbreak impacting French troops. From his research, he noticed that Shigella bacteria was the primary culprit of this affliction. He then discovered an ...
-
PROCEPT Announces 5-Year WATER Study Data Comparing Aquablation to TURP
REDWOOD CITY, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced positive five-year results from its 181 patient randomized WATER study comparing Aquablation therapy to TURP, the historical standard of care for treating BPH. WATER ...
-
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto® (mitomycin) for pyelocalyceal solution administration in the Journal of Urology online on February 7, 2022. This report provides a stepwise ...
-
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced the initiation of its Phase 3 ENVISION study of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). ENVISION is a single-arm, ...
-
« Back Northside Healthcare System in Atlanta Advances Surgical Robotics Program with Multi-System, Multi-Hospital Agreement for PROCEPT BioRobotics AquaBeam Systems
First and only image-guided, heat-free surgical robotic procedure aims to establish a new standard of care for patients with enlarged prostates REDWOOD CITY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it now has five ...
-
Asensus Surgical Provides Preliminary 2021 Year-End Corporate Update
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2021 year-end corporate update. Fourth Quarter Highlights Over 500 procedures were performed globally during the quarter, representing growth of over 25% over the ...
-
Why ISC Users Choose HR Lubricating Jelly for Self-Catheterization
Millions of people rely on self-catheterization to empty their bladder due to conditions such as urinary bladder retention, spinal cord injury, traumatic brain injury, multiple sclerosis, and more. If you are an uncoated straight catheter user, a high-quality sterile catheter lubricant is an important addition to your catheter regimen to ensure a comfortable experience and reduce pain, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you